Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
Transcenta's Osemitamab (TST001) Targeting Claudin18.2 Granted Orphan Drug Designation for Treatment of Pancreatic Cancer
2023-03-29 14:00
Antengene Announces First Patient Dosed with Claudin 18.2 Antibody-Drug Conjugate ATG-022 for the Treatment of Patients with Advanced or Metastatic Solid Tumors in Australia
2023-03-29 08:30
Innovent Announces 2022 Annual Results and Business Updates
2023-03-29 08:00
Verbal Beginnings partners with The Clinician to launch a Patient Reported Outcomes Program for Children with Autism Spectrum Disorder
2023-03-29 02:32
Antengene Announces Results for Full Year 2022 with Updates Highlighting a Sales Revenue Reaching 5.6 Times Year-Over-Year and Accelerated Global Innovation
2023-03-28 21:40
BIMINI HEALTH TECH ACQUIRES EXCLUSIVE LICENSE TO ACELLULAR DERMAL MATRIX PRODUCT PORTFOLIO
2023-03-28 21:20
New Study Reveals Clinical Instability Predicts Psychiatric Hospitalization
2023-03-28 21:00
Pulnovo Medical Announces 3-Year Follow-up Results from PADN-5 at THT 2023, The Medical Device Maker Breaks New Ground in Heart Failure Treatment
2023-03-28 20:30
WuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
2023-03-28 20:11
Sirnaomics Announces 2022 Annual Results
2023-03-28 19:26
Seegene declares to share Syndromic PCR technologies to prevent future pandemics
2023-03-28 19:00
Grey Wolf Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GRWD5769 in Patients with Advanced Solid Tumours
2023-03-28 19:00
BD and A*STAR collaborate to Advance Ultra-High Dimensional Analysis in Flow Cytometry for Immunology Research
2023-03-28 14:12
Tavneos® (avacopan) included in updated EULAR recommendations for the management of AAV
2023-03-28 13:00
HaemaLogiX to present final data from anti-KMA CAR-T preclinical studies at AACR
2023-03-28 09:43
BioDuro-Sundia Announces Formation of Scientific Advisory Board
2023-03-28 08:30
Boan Biotech Announces 2022 Financial Results
2023-03-27 23:15
YS Biopharma's PIKA Recombinant COVID-19 Vaccine Demonstrates Superior Antibody Neutralization Responses Compared to Inactivated COVID-19 Vaccine in Phase II Head-to-Head Clinical Study
2023-03-27 18:00
Noul Co. Ltd - The RIGHT Foundation Commences Research and Development for Supporting Malaria Control
2023-03-27 17:34
Everest Medicines Receives Full Upfront Payment from Gilead for Trodelvy-Related Transaction, Boosting Pro Forma Cash Reserves
2023-03-27 08:15
1
122
123
124
125
126
533